Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Colony Financial Q4 Profit Beats Estimates

RELATED NEWS
Trade CLNY now with 

Real estate finance and investment company Colony Financial Inc. (CLNY: Quote) Wednesday reported a 22 percent increase in profit for the fourth quarter on strong revenue growth. Core earnings beat analysts' expectations, while revenues missed their estimates.

The Santa Monica, California-based company's fourth-quarter net income was $13.53 million, up from $11.07 million in the previous-year quarter. However, earnings per share declined to $0.31 from $0.34 in the prior-year period on higher weighted number of shares outstanding.

Excluding items, core earnings were $18.04 million or $0.41 per share, compared to $11.86 million or $0.36 per share int the same period last year. On average, five analysts polled by Thomson Reuters estimated earnings of $0.37 per share for the quarter. Analysts estimates' typically exclude one-time items.

Total income, which includes equity in income of joint ventures and interest income, grew 70 percent in the quarter to $32.67 million from $19.18 million in the same period last year. Analysts had a consensus revenue estimate for the quarter of $33.73 million.

For fiscal 2012, Colony Financial's net income rose to $48.10 million from $42.26 million last year. However, earnings per share declined to $1.32 per share from $1.47 per share in the prior year.

Core earnings were $59.77 million or $1.65 per share, compared to $43.24 million or $1.49 per share in the previous year. Total income for the year surged 64 percent to $107.16 million from $65.47 million last year.

Analysts expected the company to earn $1.41 per share for the year on revenues of $105.72 million.

CLNY closed Wednesday's trading at $21.95, down $0.03 or 0.14 percent on a volume of 921,417 shares.

Register
To receive FREE breaking news email alerts for Colony Financial, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.